Citigroup Inc. Raises Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Citigroup Inc. increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 65.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,084 shares of the company's stock after acquiring an additional 13,874 shares during the period. Citigroup Inc. owned about 0.12% of Krystal Biotech worth $6,386,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Key Financial Inc purchased a new position in shares of Krystal Biotech in the 2nd quarter worth approximately $28,000. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after purchasing an additional 93 shares during the period. Jamison Private Wealth Management Inc. purchased a new position in shares of Krystal Biotech in the 2nd quarter worth about $28,000. Blue Trust Inc. grew its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in Krystal Biotech during the third quarter worth about $53,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on KRYS shares. Stifel Nicolaus boosted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research report on Monday, August 5th. Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $202.29.

Krystal Biotech Trading Up 0.3 %

Shares of Krystal Biotech stock traded up $0.51 on Friday, reaching $197.42. The stock had a trading volume of 116,614 shares, compared to its average volume of 283,015. The business's 50 day moving average is $180.49 and its two-hundred day moving average is $183.75. Krystal Biotech, Inc. has a 1 year low of $100.78 and a 1 year high of $219.34. The company has a market cap of $5.68 billion, a P/E ratio of 111.54 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.67) EPS. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).